The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

Balacet pulled from shelves after Darvon / Darvocet recallCornerstone Therapeutics announced this week that it would voluntarily withdraw Balacet® 325 and additional propoxyphene medications from the marketplace. The Cornerstone Therapeutics recall follows the FDA’s agreement with Xanodyne Pharmaceuticals, Inc. to withdraw name brand versions of propoxyphene: namely, Darvon®, Darvon-N®, and Darvocet-N®.

Last Friday, these painkillers were pulled from the market by Xanodyne because the drugs can cause fatal heart rhythms. The FDA said that 10 million patients took Darvon or a generic version in 2009 and 18 million prescriptions were dispensed.

"These new heart data significantly alter propoxyphene’s risk-benefit profile. The drug’s effectiveness in reducing pain is no longer enough to outweigh the drug’s serious potential heart risks," Dr. John Jenkins of the FDA’s Center for Drug Evaluation and Research said in a statement about the drug.

As part of FDA action, generic manufacturers of propoxyphene-containing products (such as Balacet ®)were requested to voluntarily remove their products as well. Propoxyphene is a mild opiate used in the treatment of mild to moderate pain, either when pain is present alone or when it is accompanied by a fever.

Two additional products affected by this decision include Cornerstone’s Propoxyphene Napsylate and Acetaminophen Tablets CIV (100 mg), and Propoxyphene Napsylate and Acetaminophen Tablets CIV (100 mg).

According to the company, net product sales of the affected Cornerstone products for the nine months ended September 30, 2010 were $8.0 million.

More information on the Darvon / Darvocet Recall.

(c) Copyright 2010 Brett A. Emison

Comments are closed.